drugset
drugset / Trial / NCT05152680

Mass Balance Study of NV-5138 in Healthy Male Subjects.

NCT05152680 ↗

Phase 1 Completed 6 enrolled Navitor Pharmaceuticals, Inc. Supernus Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to assess the mass balance and routes of excretion of total radioactivity after a single oral dose of 1600 mg \[14C\]-NV-5138.

Timeline

Start
2021-11-11
Primary completion
2021-12-09
Completion
2021-12-09

Drugs

EvaluationDrugModalityDoseRoute
Subject NV-5138 Small molecule 1600 mg Oral

Indications

No indication recorded.